Navigation Links
China Biologic Products Appoints Director of Research and Development

TAI'AN, China, Sept. 9 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company has appointed Dr. Vincent Yi-Wu Xie to be the Company's Director of Research and Development, effective September 1, 2009, to oversee the development of new biologic products covering processes, analytical methods and indications.

Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science and Technology Award in connection with his work "Preparation of Equine Antibodies against Avian Influenza." Prior to joining China Biologic, Dr. Xie served from 2007 to 2009 as the General Manager of Research and Development at New a-IKOR Limited, a Hong Kong-based biopharmaceutical company, and from 2002 to 2007, as the Director of Research & Development at Advantek Serum Laboratories Limited, a Hong Kong plasma-based biopharmaceutical company. Dr. Xie has also conducted postdoctoral research in various departments in the University of Hong Kong and the Chinese University of Hong Kong.

"We are very pleased to have Dr. Xie join our research team," commented Mr. Chao Ming Zhao, CEO of China Biologic Products. "He brings years of research experience and managerial expertise related to the biopharmaceutical industry to China Biologic Products. We expect that his presence on our team will serve to strengthen our research and development efforts as part of our strategy to bring new higher margin products to market."

About China Biologic Products, Inc.

China Biologic Products, Inc. (the "Company"), through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Chongqing Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. It sells its products to hospitals and other healthcare facilities in China.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the appointment of Mr. Xie as the Company's new Director of Research; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries, including the possibility that Mr. Xie's presence will advance the Company's strategy to bring new higher margin products to market; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact:

    Company Contact:

    China Biologic Products, Inc.
     Mr. Y. Tristan Kuo
     Chief Financial Officer
     Tel:   +86-538-6202206

    Investor Relations Contact:

    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (NY office)

     Mr. Gary Chin
     Tel:   +1-646-213-1909

SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Attend the SIG 3rd Annual Beijing Management Summit
2. Fauve Intertrade Signs Major Energy Contracts in China
3. China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
4. China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes
5. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
6. AOBOs Products Included in Chinas Essential Drug List
7. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
8. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
9. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
10. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
11. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... quality, regulatory and technical consulting, provides a free webinar on Performing ... July 13, 2016 at 12pm CT at no charge. , Incomplete investigations are ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016   Acuant , the ... solutions, has partnered with RightCrowd ® ... Visitor Management, Self-Service Kiosks and Continuous Workforce ... add functional enhancements to existing physical access ... venues with an automated ID verification and ...
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
Breaking Biology News(10 mins):